You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
BACK TO ALL NEWS/

31-01-2018

Opening of an antitrust investigation

Released: 31/01/2018 – 17:25 GMT
RNS Number: 5463D
Kedrion S.p.A.
31 January 2018

 

Castelvecchio Pascoli (Lucca, Italy), 31 January 2018 – On 10 January 2018, the Italian antitrust authority “Autorità Garante della Concorrenza e del Mercato” (“AGCM”) opened a formal investigation for potential anticompetitive conduct by Kedrion S.p.A. and Grifols Italia S.p.A.. The investigation concerns the joint participation of Kedrion and Grifols Italia through a temporary consortium (“Raggruppamento Temporaneo di Imprese”) in the tender organised by the Italian agency Intercent-ER on behalf of a grouping of regions led by Emilia Romagna. The tender, which was related to the industrial processing of plasma collected at the regional collection centers to manufacture plasma-derived pharmaceutical products, was awarded to consortium Kedrion-Grifols in September 2017.

The proceedings were initiated in accordance with Article 2 of the Italian law n. 287/1990 and Article 101 of the Treaty on the Functioning of the European Union following a complaint filed with the antitrust authority by two other companies who also participated in the tender (Baxter-Shire e CSL Behring), and should be concluded within 31 December 2018.

Kedrion S.p.A. is assessing the findings of the AGCM and cooperating with the authorities.



About Kedrion

Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies.

With over 2,400 employees and a commercial presence in around 100 countries worldwide, Kedrion works to maintain excellent industry standards and aspires to ongoing improvement in order to retain a leading position in Italy and to increase its share of the international markets. The company works to strengthen its role as the accredited partner of medical, scientific and institutional communities, and its ambition is to enhance its worldwide role as a strategic partner of the national health systems of countries, aiming to become self-sufficient in providing plasma-derived products, also via technology transfer.

Kedrion generates wealth for investors, employees and for the local community in a manner that is consistent with its own vision and values: responsibility, transparency, confidence in and respect for people.


 

Maria Lina Marcucci, Chief Communication Officer
For further information, please write to: investor@kedrion.com
Global Communication: Lisa Nordio and Tiziano Bianconcini (tel: +39 0583767628)
Corporate Finance: Pasquale Fraiese and Silvia Guidi (tel: +39 0583767494)

For more information please contact: investor@kedrion.com